1Maini R N, Feldmann M. Pocket reference to TNF-α antagonism and rheumatoid arthritis[M]. London: Science Press, 2000.
2Tolboom T C A, Pieterman E, Laan W H, et al. MMP- 1,MMP - 3 and MMP - 10 are involved in the degradation of cartilage[J]. Arthritis Res, 2001, 3(2):A1-AT.
3Redich K P, Hayea S, Ricct R, et al. Ostecolasts are essential for TNF- mediated joint destruction [J]. Arthritis Res, 2002, 4(suppl) : S45 - S47.
4Suda T, Takahashi N, Udagawa N, et al. The molecular mechanism of osteoclastogenesis: ODF/RANKL - dependent and independent pathways [J]. Arthritis Res, 2001.3(2):A1- A7.
5Maini R N, Feldmann M. How does infliximab work in rhemnatoid arthritis? [J]. Arthritis Res, 2002, 4(suppl) :S22 - S28.
6Ulfgren A K, Andersson U, Engstorm M, et al. Systeanic antitumor necrosis factor alpha therapy in rhemnatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis[ J ].Arthritis Rheum, 2000, 43 : 2391 - 2396.
7Bathon J M, Martin R W, Fleischmann R M, et al. A comparison of etanercept and methotrexate in patients with early rhemnatoid arthritis[J]. N Eng J Med, 2000, 343:1586 - 1593.
8Lipsky P E, Van der Heijde D M, St clair E W, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis[J]. N Eng J Med, 2000,343:1594-1602.
9Paleolog E M, Young S Stark A C, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interlenkin - 1 in rhetmaatoild arthritis[ J ]. Arthritis Rheum, 1998, 41 : 1258 - 1265.
10Taylor P, Patel S, Paleolog E, et al. Reduced synovial vasetdarity following TNF - a blockade in RA [ J ]. Arthritis Rheum,1998, 41(suppl) :S295 - S299.
